The macular degeneration treatment market is largely driven by rise in the incidence of retinal disorders and growing geriatric population across the world. The aging population is more likely to witness par tial loss of vision, abnormality where straight lines appear wavy, blurred vision, distorted vision, inability to witness in dim light, or spots and other macular degeneration disorders associated with pain. Between 25% and 50% of the community-dwelling elderly have been witnessing several retinal problems since the past few years. According to the data published in the European Society of Retina Specialists (EURETINA), currently, in Europe, an estimated number of 33.6 million persons over the age of 60 years are suffering from AMD. The increasing number of individuals suffering from retinal disorders is directly proportional to the market’s growth. This high prevalence rate denotes the importance of AMD treatment, primarily for treating the target disease. Furthermore, the increasing R&D investments and rising approvals for new drugs of the treatment are other major factors driving the market’s growth. Furthermore, numerous pharmaceutical manufacturers associated with the AMD market, particularly in emerging markets, such India, Brazil, and other nations witnessed significant growth and capitalized over the past decade.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPETITIVE LANDSCAPE

7. MARKET OPPORTUNITIES AND FUTURE TRENDS